Encodia is a San Diego, CA-based biotechnology company developing next-generation solutions for proteomics research. Its core product is the patented ProteoCode™ platform, which enables highly scalable protein analysis via an accessible benchtop instrument. The company says tools built on ProteoCode will drive new biological understanding with impact in data-driven drug discovery and development, new high-complexity diagnostics, and beyond. Encodia intends to use the funds to accelerate productization of ProteoCode for broad use in life science research and subsequent clinical applications. The founding team includes Drs. Mark Chee (President), Kevin Gunderson (CTO), and Michael Weiner (Board member). Financially, the company closed a $75M Series C financing to support those commercialization efforts.

Total raised

$75M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2021